Moderna Shares Skyrocket Following the Annoucement of a 94.5% Effective COVID-19 Vaccine

Shares in Moderna Inc. have shot up by 16 percent in premarket trade today after the biotech company announced its COVID-19 vaccine candidate, mRNA-1273, demonstrated 94.5 percent efficacy in a Phase 3 trial. This follows last Monday's news that Pfizer had manufactured a 90 percent effective COVID-19 vaccine, which led to an uptick in shares for movie theaters and a decline in shares within "stay-at-home" sectors, like Netflix, Zoom and Peloton. In a press release, the company outlined plans to ...